Crinetics Pharmaceuticals Inc.
Clinical trials sponsored by Crinetics Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing therapies for endocrine diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame hormone disorder Cushing's syndrome Results expected Oct 2026 (estimated)
- New pill may help adults with rare adrenal disorder cut back on steroids Results expected May 2027 (estimated)
- New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers Results expected Aug 2027 (estimated)
- New pill aims to tame flushing and diarrhea in rare cancer syndrome Results expected Aug 2027 (estimated)
-
New pill could tame rare hormone disorder
Disease control CompletedThis study tested a new oral drug called atumelnant in 38 adults with classic congenital adrenal hyperplasia, a genetic condition causing hormone imbalances. The drug works by blocking a hormone receptor to lower excess adrenal hormones. Researchers measured safety, side effects,…
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New pill could ease carcinoid syndrome Flare-Ups
Symptom relief CompletedThis Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New drug interaction study aims to make atumelnant safer
Knowledge-focused CompletedThis study is testing how a new drug called atumelnant interacts with other medications in 46 healthy adults. Participants will receive atumelnant along with drugs like carbamazepine, midazolam, digoxin, and metformin to see how the body processes them. The goal is to gather safe…
Phase 1 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Healthy volunteers help test new Drug's safety
Knowledge-focused CompletedThis study tested a new drug called atumelnant in 21 healthy adults from Japanese and Caucasian backgrounds. The goal was to see how the drug moves through the body and if it is safe. Participants took the drug or a placebo by mouth once daily. This early-stage study does not aim…
Phase 1 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC